Education
About Us
Working with TipRanks
Follow Us
DOCHERTY JOHN MARTIN Insider Profile
4 Followers
DOCHERTY JOHN MARTIN, President & CSO, Director at Lexaria Bioscience, holds 59.45K shares in Lexaria Bioscience (Ticker: LEXX). Most recently, DOCHERTY JOHN MARTIN Bought 5,376 shares of Lexaria Bioscience on Jul 30, 2025 for an estimated value of $4.95K.
DOCHERTY JOHN MARTIN has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of DOCHERTY JOHN MARTIN's holdings
Insider Roles
President & CSO, Director
Roles that DOCHERTY JOHN MARTIN holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by DOCHERTY JOHN MARTIN
DOCHERTY JOHN MARTIN's Trading History
List of latest transactions for each holding click on a transaction to see DOCHERTY JOHN MARTIN's performance on stock
You May Also Like
DOCHERTY JOHN MARTIN insider profile FAQ
What is the percentage of profitable transactions made by DOCHERTY JOHN MARTIN?
The percentage of profitable transactions made by DOCHERTY JOHN MARTIN is ―.
What is the average return per transaction made by DOCHERTY JOHN MARTIN?
The average return per transaction made by DOCHERTY JOHN MARTIN is ―.
What stocks does DOCHERTY JOHN MARTIN hold?
DOCHERTY JOHN MARTIN holds: LEXX stocks.
What was DOCHERTY JOHN MARTIN’s latest transaction?
DOCHERTY JOHN MARTIN latest transaction was an Informative Buy of $4.95K.
What was DOCHERTY JOHN MARTIN's most profitable transaction?
DOCHERTY JOHN MARTIN’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is DOCHERTY JOHN MARTIN's role in Lexaria Bioscience?
DOCHERTY JOHN MARTIN's role in Lexaria Bioscience is President & CSO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.